Pulmonary hypertension: Current criteria for diagnosis and treatment

Medicina Clinica

Volumn 118, Issue 15, 2002, Pages 590-596

  Barberà, Joan Albert ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BONE MORPHOGENETIC PROTEIN; DILTIAZEM; ILOPROST; LOSARTAN; NIFEDIPINE; PROSTACYCLIN; PROSTAGLANDIN E2 DERIVATIVE; SILDENAFIL; SMAD PROTEIN; VASODILATOR AGENT;

ALGORITHM; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; GENETIC TRANSCRIPTION; HEMODYNAMICS; HUMAN; LUNG TRANSPLANTATION; PATHOGENESIS; PROGNOSIS; PULMONARY HYPERTENSION; TREATMENT INDICATION; CLASSIFICATION; FORECASTING; NOMENCLATURE; REVIEW;

ALGORITHMS; FORECASTING; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; TERMINOLOGY;

EID: 1142280826     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(02)72461-5     Document Type: Conference Paper

References (41)

1. Primary pulmonary hypertension. A national prospective study
2. Guías de práctica clínica de la Sociedad Española de Cardiologia en tromboembolismo e hipertensión pulmonar
3. Recommendations on the management of pulmonary hypertension in clinical practice
4. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
5. Pulmonary hypertension due to toxic oil syndrome. A clinicopathologic study
6. Chronic thromboembolic pulmonary hypertension
7. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
8. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
9. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred
10. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32
11. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32
12. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene
13. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension
14. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family
15. Novel regulators of bone formation: Molecular clones and activities
16. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension
17. Abnormal pulmonary artery pressure response in asymptomatic carriers to primary pulmonary hypertension gene
18. Primary pulmonary hypertension: Natural history and the importance of thrombosis
19. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry
20. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing
21. The case for treatment of selected patients with primary pulmonary hypertension
22. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin
23. The vasodilator response to inhaled nitric oxide (iNO) predicts the short term evolution with oral vasodilators in pulmonary arterial hypertension
24. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
25. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
26. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
27. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
28. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension
29. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension
30. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus
31. Tratamiento con prostaciclina intravenosa en perfusión continua en la hipertensión pulmonar grave
32. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation
33. The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Report - 1999
34. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study
35. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial
36. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
37. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
38. Minimizing the inhaled dose of NO with breath-by-breath delivery of spikes of concentrated gas
39. Sildenafil in primary pulmonary hypertension
40. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension